Celogen Lanka Company Profile

Background

Established in 2016, Celogen Lanka has emerged as a leading pharmaceutical manufacturer in Sri Lanka. The company's mission is to provide effective and quality healthcare solutions at affordable prices, enabling people to lead healthier lives. Its vision is to become one of the world's leading and most admired pharmaceutical companies in the global generic industry by delivering international quality products and making Sri Lanka a self-reliant and competitive global player.

Celogen Lanka operates a state-of-the-art facility compliant with EU-GMP standards and approved by WHO-GMP and NMRA-Sri Lanka. As the first joint venture partner under the patronage of the State Pharmaceuticals Manufacturing Corporation (SPMC), the company plays a significant role in enhancing the domestic pharmaceutical industry.

Key Strategic Focus

Celogen Lanka specializes in manufacturing and marketing over 360 products, including tablets, hard gelatin capsules, soft gelatin capsules, suppositories, pessaries, and sachets. These products cater to various therapeutic segments such as cardiovascular, anti-diabetic, anti-infectives, gastrointestinal, nephrology, central nervous system, NSAIDs, family care, vitamins, and cosmetology.

The company's strategic focus includes:

Research and Development (R&D): Investing in R&D activities to continuously improve processes, quality, and product development.

Product Portfolio Expansion: Developing generics and technologically complex products to meet customer requirements.

Regulatory Compliance: Ensuring adherence to international regulatory guidelines and maintaining a robust Quality Management System (QMS).

Market Expansion: Extending product benefits to hospitals and clinics across Sri Lanka and exploring export opportunities in regions such as South East Asia, CIS, Middle East, Latin America, and Europe.

Financials and Funding

In November 2024, Celogen Lanka entered into a US$ 12.16 million agreement with the Board of Investment (BOI) of Sri Lanka to support its R&D initiatives. This investment aims to enhance the company's capabilities in developing advanced pharmaceutical products.

Pipeline Development

Celogen Lanka's extensive product portfolio includes over 360 products across various therapeutic segments. The company is committed to expanding its portfolio by adding new molecules, therapeutic ranges, and dosage forms to address chronic and acute diseases.

Technological Platform and Innovation

Celogen Lanka's manufacturing facility, located at the BOI Industrial Park in Pallekele, Kandy, spans 102,500 square feet and is equipped with nine production lines and six packing lines. The facility produces approximately 3,000 metric tons of pharmaceutical products annually.

The company emphasizes quality by implementing strict controls and adhering to global standards at every production stage. The facility is equipped with high-grade stainless steel, High-Definition Multimedia Interface Controlled, automatic process machines, ensuring minimal human intervention and high accuracy. The in-house laboratory features advanced equipment such as HPLCs, ICP, UV spectrometer, gas chromatography, FTIR, and stability chambers.

Celogen Lanka's R&D efforts are supported by collaborations with:

Celogen Pharma, Mumbai, India (EU-GMP approved)

Kelun Group, China

KLUS Pharma, New Jersey, USA

Zydus Research Centre, Ahmedabad, India (USFDA & EU-GMP approved)

Leadership Team

The leadership team at Celogen Lanka comprises experienced professionals dedicated to advancing the company's mission and vision. While specific names and positions are not publicly disclosed, the team includes scientists, pharmaceutical experts, and proficient management professionals who drive the company's growth and innovation.

Competitor Profile

Market Insights and Dynamics

Sri Lanka's pharmaceutical industry is heavily reliant on imports, with approximately US$ 1 billion worth of pharmaceutical products imported annually. The government's target is to reduce pharmaceutical imports by 70% by 2020, highlighting the need for domestic production.

Competitor Analysis

Key competitors in the Sri Lankan pharmaceutical manufacturing sector include:

State Pharmaceuticals Manufacturing Corporation (SPMC): A government-owned entity producing a range of essential medicines for the local market.

Cipla Sri Lanka: A subsidiary of the Indian multinational pharmaceutical company, offering a variety of pharmaceutical products in Sri Lanka.

Astron Limited: A local pharmaceutical manufacturer producing a wide range of products, including prescription and over-the-counter medicines.

These competitors focus on various therapeutic areas and have established market presence, contributing to the competitive landscape in Sri Lanka's pharmaceutical industry.

Strategic Collaborations and Partnerships

Celogen Lanka's strategic collaborations include partnerships with international research centers and pharmaceutical companies, such as Celogen Pharma in India, Kelun Group in China, KLUS Pharma in the USA, and Zydus Research Centre in India. These collaborations enhance the company's R&D capabilities and support the development of advanced pharmaceutical products.

Operational Insights

Celogen Lanka's competitive advantages include:

Advanced Manufacturing Facility: A state-of-the-art, EU-GMP compliant facility equipped with international standard machinery and instruments.

Extensive Product Portfolio: Over 360 products across various therapeutic segments, catering to diverse healthcare needs.

Strong R&D Support: Collaborations with international research centers and a dedicated team of scientists and pharmaceutical experts.

Quality Assurance: Strict adherence to global quality standards and regulatory compliance, ensuring the production of safe and effective medicines.